Latest news with #opioidaddiction
Yahoo
2 days ago
- Business
- Yahoo
Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq
We recently compiled a list of Indivior PLC stands seventh on our list among the best mid cap stocks according to billionaires. Indivior PLC (NASDAQ:INDV) is a pharmaceutical company focused on opioid addiction treatment, particularly through its flagship product SUBLOCADE, a monthly buprenorphine injection. The company has demonstrated strong growth and resilience, recently reaching a 52-week stock high. In 2025, Indivior PLC (NASDAQ:INDV) underwent a strategic leadership overhaul to strengthen its market position in the U.S., the primary arena for its operations. Joe Ciaffoni took over as CEO, bringing a fresh vision to the company, while Patrick Barry joined as Chief Commercial Officer to drive commercial expansion, especially around SUBLOCADE. Tony Kingsley also joined the board to enhance governance. These changes reflect a focused effort to boost performance and align leadership with U.S. market priorities. In line with this strategy, the business announced its plan to shift its primary listing from the London Stock Exchange to Nasdaq, aiming for greater visibility and investor engagement in the American market. Photo by Matteo Badini on Unsplash On the clinical front, Indivior PLC (NASDAQ:INDV) presented new findings at the 2025 CPDD meeting showing that higher buprenorphine exposure may improve treatment outcomes in patients with high fentanyl use, a critical step given the ongoing fentanyl crisis. The FDA also approved updated labeling for SUBLOCADE, further expanding its clinical utility. While we acknowledge the potential of INDV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
2 days ago
- Business
- Yahoo
Indivior PLC (INDV) Reinvents Leadership, Moves Listing to Nasdaq
We recently compiled a list of Indivior PLC stands seventh on our list among the best mid cap stocks according to billionaires. Indivior PLC (NASDAQ:INDV) is a pharmaceutical company focused on opioid addiction treatment, particularly through its flagship product SUBLOCADE, a monthly buprenorphine injection. The company has demonstrated strong growth and resilience, recently reaching a 52-week stock high. In 2025, Indivior PLC (NASDAQ:INDV) underwent a strategic leadership overhaul to strengthen its market position in the U.S., the primary arena for its operations. Joe Ciaffoni took over as CEO, bringing a fresh vision to the company, while Patrick Barry joined as Chief Commercial Officer to drive commercial expansion, especially around SUBLOCADE. Tony Kingsley also joined the board to enhance governance. These changes reflect a focused effort to boost performance and align leadership with U.S. market priorities. In line with this strategy, the business announced its plan to shift its primary listing from the London Stock Exchange to Nasdaq, aiming for greater visibility and investor engagement in the American market. Photo by Matteo Badini on Unsplash On the clinical front, Indivior PLC (NASDAQ:INDV) presented new findings at the 2025 CPDD meeting showing that higher buprenorphine exposure may improve treatment outcomes in patients with high fentanyl use, a critical step given the ongoing fentanyl crisis. The FDA also approved updated labeling for SUBLOCADE, further expanding its clinical utility. While we acknowledge the potential of INDV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CTV News
22-07-2025
- Health
- CTV News
‘Life-saving treatment': Siloam Mission offering opioid agonist therapy
Siloam Mission launched a new program last Wednesday in partnership with 432 Health Group and NeuroMed Mental Health and Wellness Clinic, offering help to people suffering from opioid addictions. The opioid agonist treatment (OAT) program offers medication such as Suboxone and methadone to minimize withdrawal symptoms and opioid dependence, according to Tobi Jolly, interim director of community wellness at Siloam Mission. 'It's life-saving treatment for them to manage those symptoms and to help with those cravings,' said Jolly. The new program operates seven days a week from 9 a.m. to 12 p.m. at Siloam Mission's Saul Sair Health Centre, with an on-site pharmacist and nurse practitioner. 'Having it here in our building is going to be huge for community members who might not otherwise access the treatment elsewhere.' Heidi Pharand-Joven, a nurse practitioner, said the medication is administered on-site and that patients' treatment will be tracked. She added that regular follow-ups will also be done to ensure their cravings are satisfied and that they are not feeling withdrawal symptoms. Nurse practitioner Heidi Pharand-Joven Nurse practitioner Heidi Pharand-Joven said regular follow-ups will be done as part of the program. Uploaded July 21, 2025. (CTV News Winnipeg/Jamie Dowsett) Pharand-Joven said that by ensuring people are not experiencing withdrawal—which can include pain, chills, sweats, nausea, and vomiting—they are less tempted to purchase street drugs. 'The reception has been really good, and the clients that I've met with already have just been so happy to have this service provided here,' said Pharand-Joven, noting that five people used the program on the first day. She said that some people will require OAT for life, while others may be on it for a few months or a couple of years. 'It really is a case-by-case kind of situation, and understanding that social circumstances play a huge part in people's stability and recovery.' -With files from CTV's Jamie Dowsett
Irish Times
10-07-2025
- Irish Times
Doctor who had opioid addiction is spared jail for stealing and forging prescriptions
A doctor who told a court that work stress caused his chronic opioid addiction and led him to steal and forge prescriptions is to be spared jail and a criminal record. Daniel Nevin (39) pleaded guilty at Mullingar Circuit Criminal Court to the theft of prescription pads from two hospitals, 46 counts of forgery and using false instruments between 2021 and last year. His fiancee Rebecca Moylan (35), a qualified nurse, admitted stealing prescriptions and unlawfully using them in pharmacies. Judge Keenan Johnson said these offences undermined the integrity of the medical prescription system and said Nevin was in the throes of an addiction but had never put a patient at risk. READ MORE He said the couple whose careers have been ruined and reputations tarnished had only damaged themselves, saying, 'The main victims of this are the two accused.' Nevin achieved a PhD from Trinity College Dublin, specialising in pharmacology, and had worked in medical research in Australia before returning to Ireland to continue his studies. He qualified as a medical doctor in 2018. When the addiction started in 2019 he tried to tackle the problem, but relapsed around the period of offending. Judge Johnson said Nevin was a 'high achiever', but had removed himself from working onwards as a clinician and moved into a tutoring role at Midlands Regional General Hospital. The judge was also mindful of the pressures placed on medical professionals working 24-hour shifts in busy environments. He said the couple did not reach the threshold for a custodial sentence and said they had paid a huge price. Judge Johnson said they could be spared convictions and would receive the benefit of the Probation of Offenders Act if Nevin and his fiancee donated €15,000 and €5,000 respectively to the Merchant Quay drug treatment project as a form of restorative justice. Among Nevin's charges were thefts of prescriptions from University Hospital Galway between July 2021 and July 2023 and from the Midlands Regional General Hospital in Mullingar from July 10th, 2023, until February 18th last year. The remaining charges he admitted included three counts of using false prescriptions in pharmacies in Kells, Co Meath, at Kilbeggan, Co Westmeath, and in Tullamore, Co Offaly. Moylan admitted theft of prescription pads from St James's Hospital in Dublin from September 1st, 2023, until November that year and using prescriptions forged by her partner in several pharmacies. The couple, of Greenpark Meadows, Mullingar, Co. Westmeath, used a fictitious patient's name on most of the prescriptions to get OxyContin, a highly addictive opioid-based medicine. Their offending was exposed when a pharmacist in Mullingar became suspicious in May last year, the court heard. He contacted University Hospital Galway and discovered they had no record of the prescription or the named patient. In court, Nevin agreed with his barrister, Colm Smyth SC, that the 'stress and strain of the job precipitated and aggravated' Nevin's addiction. The doctor initially managed to buy opioids online before he sought help to tackle the problem. He said after a substantial period of sobriety, he had a relapse, resulting in a prolonged absence from work and 'I took myself out of the clinician domain'. He said he switched to a teaching role in the hospital, saying he was passionate about education. Nevin said the consequences had been devastating. He expressed remorse and said he was attending addiction counselling. The court heard how Moylan, while studying to be a nurse, had cared for her terminally ill mother. Dara Foynes SC, defending, said Moylan acted out of the highest level of compassion and concern for her partner and was trying to manage a situation that was out of control, resulting in self-inflicted harm and a fall from grace. The court heard Moylan has resigned from her job, agreed not to work as a nurse again, while Nevin awaited a decision on the future of his medical career. Their court case was adjourned until Friday.
Forbes
08-07-2025
- Health
- Forbes
AI's Secret Weapon? Empathy That Builds Real Human Connection
Albert Kim is the founder and CEO of Sota Cloud, pioneering through compassionate innovation. Jade is six weeks pregnant and scared. Beyond the usual worries a young woman might face when she learns she is unexpectedly expecting, she is also battling opioid addiction. She knows that to give both her baby and herself the best chance at a brighter future, she must overcome opioid use disorder—but she's afraid to bring it up with her OB/GYN or primary care doctor. Instead, Jade turns to an online service. She explains her circumstances to a counselor via chat and is immediately met with empathy: "Jade, I appreciate you sharing your story with me. It takes great strength to recognize a problem and authentically ask for help. I have some suggestions from the American College of Obstetricians and Gynecologists on how you can begin your journey to recovery.' The counselor then provides Jade with accurate, evidence-based information about buprenorphine, a powerful medication used to help reduce opioid cravings and withdrawal symptoms as part of medication-assisted treatment (MAT), a widely accepted approach to treating opioid addiction. When AI Delivers Empathy And Accuracy At first glance, this story seems like a triumph of both technology and human empathy. The internet's power to connect people across distance supported this young mother at her most vulnerable. But there's a twist: The counselor who so deftly responded wasn't a person at all—it was an AI chatbot powered by OpenAI's GPT-4. It had been trained to provide accurate, compassionate treatment guidance to pregnant women suffering from opioid addiction. In fact, this interaction came from a recent study conducted by a University of Missouri researcher who wanted to determine whether AI could deliver both useful care advice and the kind of emotional intelligence patients often don't receive from human providers. One more clarification: Jade wasn't a real woman, but one of many simulated patients portrayed by researchers during the experiment. Still, the results speak volumes. The chatbot's responses were later reviewed by clinicians, who found them to be 96% accurate—a remarkably strong showing. What AI Empathy Means For Business Let's make this real. How does an experiment involving pregnant women relate to your business? The answer is simple: The ability to embed the kind of empathy demonstrated in this study into your own organization's digital interactions can fundamentally change how customers experience your brand. In 2025, AI virtual agents and digital assistants mediate more and more of our online conversations. A chatbot may be the first point of contact for a prospective customer. How your company—and your AI—responds in that moment may determine whether you create a loyal customer or lose a lead. But it goes even deeper than that. A positive interaction can turn a customer into an advocate. A bad one can drive them—and possibly others—away. Design For Emotional Intelligence The problem often lies in how AI has traditionally been designed. For years, the focus was on fulfilling demands, not understanding emotions. Developers may have assumed that empathy was too complex to build into a model—setting a low bar from the start. That assumption is crumbling. The addiction chatbot study is just one example of many in which AI demonstrated the capacity to deliver both accurate and empathetic responses. The implications are enormous. In your business, the way customers interact with AI is crucial to a positive outcome. Their tone, urgency and distress levels are all factors a human can follow and act upon. If your AI can detect emotional cues and act accordingly, it's no longer a command parser—it becomes a listener. When empathy is baked into your AI from the start, you're building a system that can make people feel heard, respected and supported—before a human even enters the conversation. Empathy At Every Level Of course, emotional intelligence shouldn't end with your chatbot. As CEO of a web-based dental imaging software company, I ensure that compassionate innovation is built into our operations in several ways: • Actively listening to frontline dentists and customers to improve our tools and services • Collaborating closely with vendors and suppliers to co-create solutions, not just transactions • Building long-term partnerships based on mutual respect and shared goals These relationships—internal and external—are where breakthroughs happen. Suppliers become collaborators. Customers become co-designers. Empathy becomes a competitive edge. A Clear Path Forward Looking ahead, AI brings both uncertainty and opportunity. From where I sit, one thing is becoming clearer by the day: Future success won't hinge on which company has the most advanced AI model. It will come down to which companies use AI to build stronger, more human connections. Empathy isn't soft—it's strategic. And increasingly, it's the differentiator that will separate tomorrow's leaders from the rest. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
